ASLAN Pharmaceuticals (NASDAQ:ASLN – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a report released on Tuesday, Benzinga reports. They currently have a $9.00 price objective on the stock.
Separately, Piper Sandler reaffirmed an “overweight” rating and issued a $10.00 target price (down previously from $15.00) on shares of ASLAN Pharmaceuticals in a research report on Wednesday, March 13th.
Get Our Latest Analysis on ASLAN Pharmaceuticals
ASLAN Pharmaceuticals Stock Performance
ASLAN Pharmaceuticals (NASDAQ:ASLN – Get Free Report) last announced its quarterly earnings results on Friday, April 12th. The company reported ($0.78) earnings per share for the quarter. As a group, equities research analysts predict that ASLAN Pharmaceuticals will post -2.68 EPS for the current year.
ASLAN Pharmaceuticals Company Profile
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1 subunit which is being developed for the treatment of atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune diseases.
Featured Stories
- Five stocks we like better than ASLAN Pharmaceuticals
- How to Capture the Benefits of Dividend Increases
- High-Yield Texas Instruments Could Hit New Highs Soon
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for ASLAN Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ASLAN Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.